Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112684 · ClinicalTrials.gov registry record · Phase 1
Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00112684: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00112684 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00112684, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of alvocidib in treating patients with locally advanced or metastatic solid tumors. Drugs used in chemotherapy, such as alvocidib, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Alvocidib may also stimulate the immune system in different ways and stop tumor cells from growing. It may also stop the growth of solid tumors by blocking blood flow to the tumor.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG alvocidib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00112684
The ClinicalTrials.gov registry entry for NCT00112684 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00112684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00112684 about?
NCT00112684 is a clinical study titled "Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors". This phase I trial is studying the side effects and best dose of alvocidib in treating patients with locally advanced or metastatic solid tumors. Drugs used in chemotherapy, such as alvocidib, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them f...
What is the current status of trial NCT00112684?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2006-02.
What interventions are being tested in trial NCT00112684?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), alvocidib (DRUG).
Who is sponsoring clinical trial NCT00112684?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.